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Abstract 26 
Dental caries is a common bacterial infection, but the progression of this disease can 27 
be delayed by preventing initial attachment of cariogenic bacteria such as 28 
Streptococcus mutans to tooth surfaces. This study firstly compares the effect of 29 
untreated (UT) and enzyme-treated (ET) dairy powders on the adherence of S. mutans 30 
to hydroxylapatite (HA), an analogue of tooth enamel. A fluorescence-based method 31 
was used to quantify adherence of S. mutans to HA both in the presence (S-HA) and 32 
absence (PBS-HA) of saliva. Secondly, binding of proteins present in the test 33 
materials to HA was quantified using bicinchonic acid assays and SDS-PAGE. In 34 
addition, the effect of UT and ET dairy powders on growth of S. mutans was 35 
examined using an optical-density based assay. UT acid whey protein concentrate 36 
(WPC) 80, sweet WPC80, buttermilk powder (BMP) and cream powder (CP) 37 
significantly (P<0.05) inhibited adhesion of S. mutans at ≥31.25μg mL-1 in the 38 
presence and absence of saliva. ET dairy powders were less effective inhibitors of 39 
adhesion, but ET sweet WPC80 significantly (P<0.05) inhibited growth of S. mutans 40 
at ≥0.6mg mL-1. Therefore, due to their adherence- and growth-inhibitory properties, 41 
dairy powders may be beneficial in the treatment of dental caries.  42 
 43 
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1. Introduction 51 
Dental caries affects both children and adults, and is regarded as one of the 52 
most common bacterial infections in humans (Aas, Paster, Stokes, Olsen, & Dewhirst, 53 
2005). Individuals are susceptible to this disease throughout their lifetime (Sewitz, 54 
Ismail, & Bitts, 2007). Streptococcus mutans is considered to be the primary 55 
etiological agent involved in formation of dental caries (Loesche, 1986). Once 56 
adhered to the buccal surfaces, acid(s) formed by oral bacteria due to fermentation of 57 
sugars accumulate in plaque on the teeth, and in turn contribute to tooth decay 58 
(Loesche, 1986). Adhesion of a pathogenic microorganism to a host tissue is 59 
considered to be a vital step in colonisation and subsequent infection (Finlay and 60 
Falkow, 1997). Over 25 years ago, Beachey (1981) proposed the design of therapies 61 
to prevent initial adherence of a pathogen to surface receptors, thus blocking the 62 
prerequisite step of infection. Therefore, a logical approach to preventing initiation of 63 
the dental caries process centres upon inhibiting the adherence of cariogenic bacteria 64 
such as S. mutans to the tooth surface (Tarsi, Muzzarelli, Guzman, & Pruzzo, 1997). 65 
Many effective anti-adhesion agents have been identified in foods and beverages 66 
(Ofek, Hasty, & Sharon, 2003), such as herbal extracts (Limsong, Benjavongkulchai, 67 
& Kuvatanasuchati, 2004), cranberry juice (Yamanaka, Kimizuka, Kato, & Okuda, 68 
2004), and water-soluble protein fraction (WSPF) from hen egg yolk (Gaines, James, 69 
Folan, Baird, & O’Farrelly, 2003). In addition, some constituents of human milk are 70 
known to be capable of binding to pathogenic microbes and inhibiting their adherence 71 
to host surfaces (Ofek et al., 2003). It is possible that the equivalent components of 72 
bovine milk (and products thereof) could have similar anti-adhesion effects.           73 
Research has shown that bovine milk components, including whey 74 
components, possess biological activity (Brody, 2000). Whey protein has attracted 75 
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considerable interest as it has become evident that many of its constituents exhibit 76 
bioactive properties (Marshall, 2004). Whey protein is made up of β-lactoglobulin 77 
(50%), α-lactalbumin (20-25%), bovine serum albumin (10-15%), immunoglobulins 78 
(10-15%), lactoferrin (0.35 to 2%) and lactoperoxidase (0.25-0.5%) (Madureira, 79 
Pereira, Gomes, Pintado, & Malcata, 2007). Also, sweet whey contains 80 
glycomacropeptide (GMP) at concentrations of up to 15% (Madureira et al., 2007).   81 
Peptides derived from these precursor proteins are known to have antibacterial 82 
properties (Madureira et al., 2007), with enzymatic digestion being the most common 83 
method used to produce such peptides (Kurhonen, 2009). In addition, it has been 84 
reported that peptides possessing antibacterial activity can also exhibit other 85 
biological activities relating to protection of the host (Lopez-Exposito & Recio, 2006). 86 
Peptide-based therapeutic agents from natural substrates (such as dairy products) that 87 
can be added to food, toothpaste and mouthrinses are increasingly in demand as an 88 
approach to delay progression of caries (Hayes, Ross, Fitzgerald, Hill, & Stanton, 89 
2006).  90 
A non-protein constituent of whey which may contribute to its bioactive 91 
properties is milkfat. This component may also have potential to inhibit dental caries, 92 
as it contains triglycerides and lipids that can exhibit antimicrobial effects either 93 
directly or following enzymatic digestion (Sprong, Hulstein, & van der Meer, 2002). 94 
The spectrum of saturated fatty acids in milkfat can vary in chain-length from C4 to 95 
C18, while also containing the unsaturated fatty acids C18:1 and C18:2 (Sprong, Hulstein, 96 
& van der Meer, 2001). It has been reported that the medium-chain fatty acids C8 - 97 
C12 can have a bacteriostatic effect on dental plaque bacteria (Schuster, 1980). 98 
Research recently carried out in this laboratory has shown a range of 99 
commercial dairy powders (including whey products such as whey protein 100 
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concentrates and whey protein isolates, along with buttermilk powder and cream 101 
powder) are capable of inhibiting adherence of S. mutans to hydroxylapatite (HA) 102 
(Halpin et al., 2008). HA is a calcium-phosphate analogue of teeth commonly used as 103 
an in vitro model (Gibbons, Moreno, & Spinell, 1976, Clark & Gibbons, 1977, Gaines 104 
et al., 2003) of adherence of oral bacteria to tooth surfaces.  Also, it has been claimed 105 
that a commercial whey product (Carbelac 80) can inhibit both growth and adherence 106 
of S. mutans following treatment with porcine pancreatic lipase (PPL) (Brady & 107 
Folan, 2003). Further to this, a separate study by Halpin, Brady, O’Riordan, & 108 
O’Sullivan (2009) showed a range of commercial whey products reduced association 109 
of enteric pathogens to CaCo-2 cells, and that the anti-adherence effect was enhanced 110 
following PPL-treatment of the whey products. 111 
As whey contains both protein and fat, enzymatic digestion can potentially 112 
liberate an array of peptides and fatty acids, respectively. In the present study, a varied 113 
range of whey and dairy products which were previously found to effectively reduce 114 
adherence of S. mutans to phosphate-buffered saline-coated HA (PBS-HA) (Halpin et 115 
al., 2008) were subjected to enzyme-treatment in order to determine if this would 116 
increase their anti-adhesion activity. Therefore, the main objective of the present 117 
study was to examine the effect of enzyme-treatment on the anti-adhesion efficacy of 118 
these dairy powders, using both PBS-HA and saliva-coated HA (S-HA). Association 119 
of the proteinaceous component of a selection of dairy powders to HA beads was also 120 
investigated. In addition, the effect of both untreated and enzyme-treated dairy 121 
powders on the growth of S. mutans was examined.  122 
2. Materials and Methods  123 
2.1 Bacterial Isolates and Growth Conditions  124 
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A clinical isolate of S. mutans (LAN-SVHERC-1997sm1) was obtained from the 125 
Microbiology Department, St. Vincent’s University Hospital, Dublin, Ireland. 126 
Bacteria were maintained on Protect™ Bacterial Preserve beads (Technical Service 127 
Consultants Ltd, Lancashire, UK) at -80˚C. A single bead from the frozen stock 128 
culture was used to inoculate a Columbia blood agar plate (CBA: Oxoid, Hampshire, 129 
England) and grown aerobically at 37˚C for 48 h. A single colony from the blood agar 130 
plate was subsequently used to inoculate 20mL of brain heart infusion (BHI) broth 131 
(LabM, Lancashire, UK) and grown under aerobic conditions without shaking at 37˚C 132 
for 18 h. 133 
2.2 Source and Characterisation of Dairy Powders  134 
Sweet whey protein concentrate 80 (SWPC80), acid WPC 80 (AWPC80), sweet WPC 135 
35 (SWPC35), whey protein isolate (WPI), whey powder (WP) and demineralised 136 
whey (DW) powders were supplied by Carbery Milk Products (Ballineen, Cork, 137 
Ireland). The principal differences in composition between SWPC80 and SWPC35 138 
should be noted. Although both of these whey products are derived from sweet whey, 139 
SWPC80 contains 80% protein (i.e. 80 grams of protein per 100g of product) and only 140 
6% lactose (i.e. 6 grams of lactose per 100g of product). However, SWPC35 contains 141 
almost 35% protein and approximately 51% lactose. In addition, SWPC35 contains 142 
only half of the amount of fat that is present in SWPC80 (refer to Table 1).   143 
Buttermilk powder (BMP) and cream powder (CP) were supplied by Kerry Group plc 144 
(Tralee, Co. Kerry, Ireland). Albumin from chicken egg white (grade V) and lactose 145 
were supplied by Sigma (Poole, Dorset, UK).  146 
Compositional analysis was performed on each dairy product using standard methods. 147 
Ash content was analysed according to Malkomesius & Nehring (1951). Fat content 148 
was determined according to the method of Röse-Gottlieb (International Dairy 149 
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Federation, IDF, 1987), protein content was determined by the Kjeldahl method (IDF, 150 
1993a) and the moisture content was determined by the IDF reference method (IDF, 151 
1993b). 152 
2.3 Hydrolysate Preparation Conditions 153 
Crude porcine pancreatic lipase (PPL, 100-400 units/ mg protein) (Sigma, Poole, 154 
Dorset, England) was used throughout the study. Preliminary experiments 155 
demonstrated the presence of both peptidase and lipase activities in this enzyme 156 
preparation (data not shown). Hydrolysates were prepared in a Fermac 200 fermentor 157 
(Electrolab Ltd, Tewkesbury, UK) as follows: a c. 2% (g/100mL) solution of substrate 158 
was prepared by dissolving 20g of dairy powder in 900mL of sterile distilled water 159 
and heating at 37˚ C with stirring for 30 min. Lipase solution (1g of PPL in 100mL of 160 
sterile H20) was added to the substrate solution to give a final incubation volume of 1 161 
L. The substrates were then incubated for 18 h at 37˚C with stirring. The resulting 162 
hydrolysates were heated at 60˚C for 10 min in order to denature the enzyme(s). Each 163 
hydrolysate was then placed on ice and allowed to cool to less than 10˚C (approx. 45 164 
min), before being frozen using liquid nitrogen and subsequently lyophilised 165 
(Moduloyo, Edwards High Vacuum, Manor Royal, Crawley, Sussex, UK).                                                                                                                 166 
2.4 Adhesion Assay 167 
2.4.1 (a) Preparation of Hydroxylapatite 168 
Hydroxylapatite (HA) beads were supplied by Merck (Darmstadt, Germany). Both 169 
phosphate buffered saline-coated and saliva-coated HA were used throughout the 170 
study. Particle size analysis using a Malvern Mastersizer (Malvern Instruments Ltd., 171 
Worcestershire, UK) showed the average diameter (D [4,3]) of the HA beads to be 172 
approximately 10μm. Phosphate-buffered saline coated HA (PBS-HA, PBS: Oxoid, 173 
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Hampshire, England) was prepared by suspension of 7.5mg mL-1 HA in PBS 174 
immediately before use in the adherence assays.  175 
Saliva-coated-HA (S-HA) was prepared by a modification of the protocol set out by 176 
Gibbons & Etherden (1982) as follows: parafilm-stimulated whole saliva was 177 
collected in an ice-chilled tube from two healthy donors (1 male, 1 female) at least 1 h 178 
after eating, drinking or brushing of teeth. The saliva was heated at 60ºC for 30 min to 179 
inactivate degenerative enzymes, and subsequently centrifuged at 12,000 × g for 15 180 
min. The pellet was discarded and the supernatant (i.e. clarified whole saliva) was 181 
used to prepare a 7.5mg mL-1 dispersion of HA. Aliquots (150μL) of saliva-coated 182 
hydroxylapatite (S-HA) were dispensed into the wells of a 96-well V-bottomed plate 183 
(Sarstedt, Newton, North Carolina, USA), and incubated at 30ºC for 1 h with gentle 184 
agitation (4.5 × g). Following this, the microtitre plate was centrifuged at 805 × g for 185 
2 min, the supernatants discarded and the S-HA pellets washed twice with sterile pre-186 
warmed PBS to remove excess saliva. The S-HA pellets were subsequently 187 
resuspended in sterile PBS for use in the adherence assay.  188 
2.4.1 (b) Preparation of Syto 13 dye 189 
Syto 13 dye (Molecular Probes, Oregon, USA) was supplied as a 5mmol L-1 190 
solution in dimethylsulphoxide (DMSO). This concentration was adjusted to 5μmol L-191 
1 by appropriate dilution in sterile PBS, and was used only on the day of preparation. 192 
A standard curve of relative fluorescent units (RFU) versus CFU mL-1 was 193 
constructed for S. mutans (R2= 0.9942). 194 
2.4.2 Assay Protocol 195 
An overnight culture of S. mutans was centrifuged at 3220 × g (Eppendorf 5810R, 196 
Cambridge, UK) for 10 min and the pellet resuspended in sterile PBS. Following a 197 
second centrifugation step, the bacterial pellet was resuspended in PBS, and the 198 
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OD630nm of the suspension measured using a Multiskan Ascent spectrophotometer 199 
((Thermo Electron Corporation, Vantaa, Finland), and adjusted to 0.2 by appropriate 200 
dilution with sterile PBS. 201 
The adherence assays were carried out as previously described (Halpin et al., 2008), 202 
using sterile 96-well polystyrene microtitre half-area plates (Nunc, Roskilde, 203 
Denmark). Dairy powders were prepared to the required concentration by dispersing 204 
the dried powder in PBS. Briefly, 50μL of test material solution at various 205 
concentrations was added to the wells, followed by 50μL of PBS-HA or S-HA (7.5 206 
mg mL-1). Bacterial suspension (50μL) was added to the wells, so that the final 207 
volume of each well was 150μL. Control wells (no bacteria and/ or no HA) were 208 
included in each assay. The plate was incubated at room temperature for 45 min, and 209 
manually inverted at 5 min intervals to prevent settling of the HA suspension. The 210 
plate was subsequently centrifuged at 201 × g to sediment the HA and any adhering 211 
bacteria, leaving the non-adhering bacteria in suspension. These non-adhering bacteria 212 
were labelled with 10μL of 5μmol L-1 Syto® fluorescent dye. For more information 213 
regarding the development and validation of the assay described here, the reader 214 
should refer to Halpin et al., 2008. 215 
2.5 Quantification of Bacterial Adherence  216 
Aliquots (100μL) of supernatant from the adherence assay (Section 2.4.2) containing 217 
the non-adhering bacteria were transferred from each well of the half-area plate to the 218 
corresponding wells of a black microtitre plate (Costar, Corning Inc., Corning, USA). 219 
This plate was allowed to stand at room temperature for 5 min in the dark before 220 
reading the fluorescence using a Fluoroskan Ascent plate reader (Thermo Electron 221 
Corporation, Vantaa, Finland). The excitation wavelength was 485 nm and the 222 
emission intensity was monitored at 538 nm. Three measurements were taken at 5 min 223 
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intervals, and the average fluorescence calculated. The fluorescence due to the total 224 
number of bacteria present in the supernatant was determined as a direct readout from 225 
the fluorimeter as relative fluorescent units (RFU). The background fluorescence due 226 
to non-bacterial components of the assay (i.e. dairy powder and HA) were subtracted. 227 
The percentage inhibition of adhesion was calculated as follows: 228 
( )
( )
Fluorescence due to unbound bacteria
Fluorescence due tototal input bacteria
× 100                   (1) 229 
2.6 Protein Adherence Assay 230 
The ability of the proteinaceous component of the various dairy powders to adhere to 231 
the HA beads was assessed as follows; a dispersion of HA (20 mg mL-1) was mixed 232 
with an equal volume of test material at various concentrations, so that the final 233 
concentration of test material ranged from 0.0625mg mL-1 to 1mg mL-1. The mixture 234 
was gently inverted at 5 min intervals for a period of 45 min, before being centrifuged 235 
(201 × g, 10 min). Supernatants were subsequently decanted into plastic tubes and 236 
shaken vigorously before determination of protein content by the bicinchonic acid 237 
(BCA) method (Smith et al., 1986), for which all reagents were supplied by Sigma 238 
(Poole, Dorset, UK). Aliquots (25μL) of supernatant were added to wells of a 96-well 239 
plate, followed by 200μL of BCA reagent, and the plate was subsequently incubated 240 
for 30 min at 37˚C. A plate reader (Spectra Max; Molecular Devices Corp., U.K.) was 241 
used to measure sample absorbance values. Absorbance was measured at 570nm 242 
(Abs570nm), and readings were converted to mg mL-1 protein using a standard curve of 243 
absorbance versus protein concentration (R2= 0.9983), which was prepared using 244 
bovine serum albumin (BSA; Sigma, Poole, Dorset, UK).  245 
2.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  246 
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To investigate the selectivity of any HA/ protein interactions, the protein profiles of 247 
the resulting supernatants from the protein adherence assay were compared to that of 248 
the starting material by SDS-PAGE (Laemmli, 1970) using the Bio-Rad protein mini-249 
gel system (Bio-Rad Laboratories, Richmond, California). Briefly, this was achieved 250 
by incubating untreated WPCs with HA beads or alone (as described in Section 2.6). 251 
Sedimentation recovered the HA beads along with any bound protein, leaving 252 
unbound protein in the supernatant which was quantified using SDS-PAGE. All 253 
reagents were purchased from Sigma (Poole, Dorset, UK). Resolving gel and stacking 254 
gel were prepared to 15g/100mL and 4g/100mL acrylamide, respectively. In order to 255 
visualise protein bands, gels were stained using coomassie blue dye. Protein bands 256 
were quantified using densitometry software (Alphaview Version 1.3.0.7, Innovatech 257 
Corporation). 258 
2.8 Growth Assays 259 
Growth assays were carried out in sterile 96-well plates (Nunc, Roskilde, Denmark). 260 
Overnight cultures of S. mutans were prepared in BHI broth as described earlier 261 
(Section 2.1). A working culture containing c. 108 colony forming units per millilitre 262 
(CFU mL-1) was prepared by adding 1mL of overnight culture to 9mL of sterile BHI 263 
broth. Test materials were prepared by dispersing dried dairy powders or hydrolysates 264 
in BHI broth to the desired concentration. Aliquots (100μL) of test material were 265 
added to the wells of the plate, followed by 100μL of the diluted culture; the final 266 
concentrations of test material were 0.6mg mL-1, 1.25mg mL-1, 2.5mg mL-1 and 5mg 267 
mL-1. Bacterial growth in the absence of test material (i.e. control growth) was also 268 
determined. The plate was then incubated at 37˚C for 18 h in a Multiskan Ascent plate 269 
reader (Thermo Electron Corporation, Vantaa, Finland). Immediately prior to 270 
incubation the plate was shaken for 1 min in order to disperse the suspensions. The 271 
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optical density (OD) readings at 630nm for each well were subsequently recorded at 1 272 
h intervals, with the plate being shaken for 30 s immediately prior to measurement. 273 
The initial OD reading, recorded at time 0, of each well was subtracted from all other 274 
readings for the corresponding wells over the 18 h incubation time (i.e. to subtract the 275 
background OD values).  276 
2.9 Solid Phase Micro Extraction / Gas chromatography (SPME/GC) headspace 277 
analysis of short chain fatty acids (SCFAs) 278 
SPME/GC analysis was performed in order to confirm the presence of the free fatty 279 
acids butanoic (C4) and hexanoic (C6) in SWPC80 post-hydrolysis with PPL. This 280 
was carried out according to the method of Noronha, Cronin, O’Riordan, & 281 
O’Sullivan (2008). Briefly, GC analysis was performed on an ATI Unicam Model 282 
6100 gas chromatograph fitted with a flame ionisation detector (FID) and interfaced 283 
to a Spectra-Physics SP4290 computing integrator. The column used was a 15 m 284 
FFAP (Quadrex Inc.) fused silica column (0.53 mm i.d., film thickness, 1μM). 285 
Hydrogen was used as a carrier gas at a flow rate of 8mL min-1. The column 286 
temperature was 140˚C and the injection block was set at 300 ˚C. The volatile SCFAs 287 
(C4 and C6) present in the aqueous dairy powder hydrolysate (20 g L-1) samples were 288 
measured by SPME headspace analysis using iso-butanoic (iso-C4) and 4-methyl-289 
pentanoic acids (4-Me-C5) as internal standards (IS), respectively, at various time-290 
points after addition of the PPL. The SPME fibres (Carboxen/ PDMS, 75μM 291 
thickness) were obtained from Supelco (Supelco-Aldrich, Dublin, Ireland) and were 292 
conditioned under a flow of nitrogen (10mL min-1) at 300˚C for 2.5h prior to use. 293 
An aliquot (20 mL) of the hydrolysate was transferred to a 10 mL screw thread glass 294 
vial, fitted with a magnetic stirring bar. After sealing the vial with a 295 
polytetrafluoroethylene (PTFE) silicone rubber septum, the SPME needle was 296 
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inserted through the latter so as to position the fibre 15 mm above the surface of the 297 
liquid hydrolysate. The hydrolysate was heated with stirring by placing the vial in a 298 
thermostatically controlled water bath at 50˚C. After equilibration for 10 min, the 299 
headspace was sampled by exposing the fibre for 10 min. The concentration of the 300 
volatile fatty acids (VFAs) was determined using the following equation: 301 
 302 
Concentration of analyte (C4 or C6)  303 
= peak area of analyte × concentration IS 
peak area of IS × response factor × sample volume
              (2) 304 
The response factors for the two analytes were established by carrying out SPME 305 
headspace analysis of an aqueous standard (0.2g L-1 each of C4, iso-C4, C6 and 4-Me-306 
C5 acids) under the same conditions as described above for the liquid hydrolysate 307 
samples. 308 
Response factor (C4 or C6) = 4
4
peak area C  
peak area iso-C
 or 6
5
peak area C  
peak area 4-Me-C
        (3) 309 
The response factor was calculated as 1 for both C4 and C6. GC retention times of the 310 
SCFAs were 2.2, 2.8, 5.6 and 6.6 min for iso-C4, C4, 4-Me-C5 and C6, respectively.  311 
2.10 Statistical Analysis 312 
All adherence/ growth assays were performed at least three times (n=3). Results were 313 
expressed as the mean ± standard deviation (S.D.). Differences between 314 
concentrations within treatments were determined using the least significant 315 
difference (LSD) test, while differences between treatments were determined using 316 
Duncan’s test. Both analyses were performed using SAS Version 9.1.3. Data were 317 
considered significantly different if P<0.05. 318 
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3. Results 319 
Compositional analysis of the dairy powders (fat, protein, moisture, ash and lactose) 320 
was determined (Table 1). These were typical of their product types. Sweet and acid 321 
WPC80s have similar protein and fat contents, while WPI has almost no fat. WP and 322 
DW contain less protein and fat than the WPCs and WPI, but have a high content of 323 
lactose. SWPC35 also contains high levels of lactose when compared to the 324 
WPC80’s, WPI and CP. BMP contained less protein than the WPCs and WPI, and CP 325 
had the highest fat content of the test materials. 326 
3.1 Adherence Assays  327 
(a) Adhesion to phosphate buffered saline-coated hydroxylapatite 328 
A small proportion of S. mutans did not bind to PBS-HA (c. 15%) under our 329 
experimental conditions (shown as the ‘control’ value in Table 2). Of the untreated 330 
dairy powders, AWPC80 appeared to be the most effective inhibitor of S. mutans 331 
adhesion to PBS-HA at the concentrations examined (Table 2), increasing the non-332 
binding proportion of bacteria to c. 93%. However, at 125µg mL-1, UT BMP and UT 333 
CP were equally as effective (P>0.05). The protein control, egg albumin, did not 334 
reduce adhesion at all, and resulted in similar non-binding proportions of S. mutans as 335 
were observed in the absence of test material (i.e. control adherence).  336 
In most cases, enzyme treatment was found to reduce the anti-adhesion activity of all 337 
dairy powders (Table 2), in that the proportion of non-binding bacteria was markedly 338 
lower for the ET dairy powders than those observed for the equivalent UT samples. At 339 
125μg mL-1, enzyme treatment significantly (P<0.05) reduced the anti-adhesion 340 
activity of all dairy powders with the exception of WP. None of the enzyme-treated 341 
dairy powders caused the non-binding proportion of S. mutans to increase to levels 342 
≥40% in the PBS-HA assays. ET CP was the most potent inhibitor of S. mutans 343 
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adhesion to PBS-HA at 31.25μg mL-1, and ET CP and ET SWPC80 were found to be 344 
equally as effective (P>0.05) inhibitors at 62.5µg mL-1 and 125µg mL-1.  345 
Lactose, which was present in all test materials at varying levels, was not found to 346 
affect adherence of S. mutans to PBS-HA, even when used at concentrations up to 347 
1000μg mL-1 (data not shown), and in fact was found to significantly increase the 348 
adherence of S. mutans to PBS-HA (P<0.05). 349 
(b) Adhesion to saliva-coated hydroxylapatite 350 
In the presence of saliva, the control level of adhesion of S. mutans to hydroxylapatite 351 
was significantly reduced when compared to that of the PBS-HA model (P<0.0001), 352 
with c. 37% of each bacterial culture not adhering to S-HA (‘control’ in Table 3). 353 
At concentrations ≥ 31.25µg mL-1, UT SWPC80, AWPC80 and BMP significantly 354 
(P≤0.05) reduced adherence of S. mutans to S-HA relative to the protein control (egg 355 
albumin, EA).  At 62.5µg mL-1 and 125µg mL-1, UT SWPC80, UT AWPC80 and UT 356 
WP were the most potent inhibitors of S. mutans adhesion to S-HA, being more 357 
effective than all other UT test materials and increasing the proportion of non-binding 358 
bacteria to 75-80%. 359 
Consistent with our observations in the PBS-HA model system, untreated dairy 360 
powders were generally more potent inhibitors of S. mutans adherence than the same 361 
powders following enzyme-treatment, except in the case of the WPCs, which were 362 
found to show similar levels of efficacy both in their untreated and enzyme-treated 363 
forms. However, it is worthwhile to note that the reduction in anti-adhesion activity 364 
caused by enzyme treatment of powders was not as dramatic in the case of S-HA as 365 
that observed in the PBS-HA model. Following enzyme treatment, at 31.25µg mL-1, 366 
all powders excluding ET WPI, ET WP and ET DW significantly inhibited adherence 367 
of S. mutans to S-HA relative to the control (P<0.05). However, at 125µg mL-1, all 368 
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enzyme treated dairy powders were more effective than egg albumin (P<0.05), with 369 
most ET dairy powders showing similar levels of anti-adhesion.  370 
3.2 Adherence of Whey and Dairy Powders to PBS-HA 371 
The more effective inhibitors of S. mutans adherence to PBS-HA were used to 372 
establish if protein present in the test material was adhering to the HA beads.  Table 4 373 
shows the relationship between the initial protein concentrations of these dairy 374 
suspensions and the amount of protein associated with HA. When sedimented from 375 
solutions of increased protein content, the amount of protein associated to the HA 376 
increased with increasing protein concentration in all cases, but to different extents, 377 
perhaps suggesting dairy powders possessed different affinities for HA. Of the 378 
materials examined, the greatest level of protein association was observed in the case 379 
of AWPC80, which was also observed to be the most potent inhibitor of S. mutans 380 
adherence to PBS-HA (Table 2).  381 
3.3 SDS-PAGE of Protein Content of WPC Supernatants Before and After 382 
Incubation with PBS-HA 383 
The electrophoresis patterns of UT SWPC80, UT AWPC80 and UT SWPC35 before 384 
and after incubation with and separation from HA are compared in Figure 1. 385 
Densitometric analysis of the protein bands confirmed that the total protein content of 386 
each WPC was reduced following incubation with HA. Protein contents of UT 387 
SWPC80, UT AWPC80 and UT SWPC35 were reduced by 66.7%, 53.9% and 59.4%, 388 
respectively. Most notably, the larger proteins (possibly the heavy and light chains of 389 
the immunoglobulins and BSA) appeared to have associated with HA, as these bands 390 
are not present following incubation with HA.  391 
In addition, densitometric analysis indicated that the protein bands representing β-lac 392 
were reduced by 51%, 41% and 63.2% for UT SWPC80, UT AWPC80 and UT 393 
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SWPC35, respectively. No reduction in intensity was observed for the bands 394 
representing α-lac following incubation with HA, suggesting this whey protein did 395 
not adhere to the HA beads.  396 
3.4 Growth Inhibition Assays 397 
None of the untreated (UT) dairy powders inhibited growth of S. mutans at any of the 398 
concentrations examined (0.6-5mg mL-1) (data not shown). Of the ET dairy powders, 399 
growth inhibition of S. mutans was most evident for ET SWPC80 (Figure 2). Growth 400 
of S. mutans was significantly inhibited (P<0.05) at all concentrations examined, and 401 
the effect showed a slight concentration dependency Comparison of the rates of 402 
increase of OD630 during the logarithmic growth phase suggests that the maximum 403 
concentration of ET SWPC80 (5mg mL-1) used reduced the rate of growth by more 404 
than 2-fold over that of the control.  405 
3.5 Determination of Volatile Fatty Acids in ET SWPC80 406 
Aqueous hydrolysate samples were taken at 15 min intervals following addition of 407 
lipase solution and SPME/GC performed at each time point. Levels of C4 and C6 408 
appeared to ‘level off’ after c. 60 min, and were present at levels of 52.28 ± 6.68μg 409 
mL-1 and 18.66 ± 1.49μg mL-1, respectively, after 120 mins of hydrolysis time.  410 
4. Discussion            411 
The findings of a previous study by this group showed that a range of UT dairy 412 
powders reduced adherence of S. mutans to PBS-HA (Halpin et al., 2008). The 413 
present study examined the effect of enzyme-treatment on the anti-adhesion activity 414 
of these powders, using two model systems: PBS-HA and S-HA. The S-HA model 415 
represents the closest approximation to conditions in the oral cavity, while the PBS 416 
model system represents a cleaner working matrix and may also serve as a model for 417 
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in vivo conditions where saliva production is impaired, e.g. in cases of ‘dry mouth’. 418 
Dry mouth, also referred to as xerostomia, describes a variety of conditions whereby 419 
salivary flow rate is reduced, and individuals with this condition are susceptible to 420 
rampant caries (Loesche, 1986).  The authors do however acknowledge that dry 421 
mouth patients do not have teeth free from a protein film (so called ‘pellicle’) and 422 
bacterial biofilm, but that the proteins adhering to the tooth tissues are of origins other 423 
than saliva, i.e. gingival pockets, exudate from the soft tissues, and of course, foods.  424 
Under our experimental conditions, control adherence varied greatly between PBS-425 
HA and S-HA, which resulted in a different ‘starting point’ as such for assessing the 426 
efficacy of the test materials. The more effective test materials (UT AWPC80, UT 427 
SWPC80, UT BMP and UT CP) increased the proportion of S. mutans not adhering to 428 
PBS-HA to a level similar to or greater than those observed in the presence of saliva. 429 
For example, control adherence of S. mutans was typically 40% for S-HA, and the 430 
proportion of bacteria not adhering to PBS-HA far exceeded this value in the presence 431 
of the dairy powders listed above. Thus, dairy powders may be useful ingredients in 432 
the development of a beverage which could potentially act as a saliva substitute. It has 433 
previously been reported (Johansson, 2002) that milk and dairy-based drinks possess 434 
many of the biological and physical attributes that would make them suitable saliva 435 
substitutes, and the current investigation provides substantiating evidence that this 436 
may be a useful application for dairy products.  437 
Experiments have shown that proteins present in these dairy powders are 438 
interacting with the HA beads and this may, in part at least, be contributing to the 439 
reduction in adherence of S. mutans to PBS-HA. This observation was confirmed by 440 
results from SDS-PAGE, which further suggested that some of the larger proteins in 441 
the WPCs such as the immunoglobulins and BSA had associated with the HA beads. 442 
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Of the UT dairy powders, AWPC80 was found to be the most effective inhibitor of S. 443 
mutans adhesion to HA, and exhibited the highest level of protein association with 444 
HA beads. However, the level of protein associating with HA varied between test 445 
materials, and a high protein content did not necessarily lead to higher levels of 446 
interaction with HA beads, suggesting other factors were contributing to inhibition of 447 
adherence. Furthermore, it is possible that the test materials are also interacting with 448 
the bacterial cells, and this may in turn reduce the ability of the cells to adhere to 449 
surfaces. 450 
Although UT AWPC80, UT SWPC80, UT BMP and UT CP were found to be 451 
very effective inhibitors of S. mutans adherence to both PBS-HA and S-HA, the active 452 
component(s) of each of these test materials may not be the same. To begin with, the 453 
compositions of these dairy powders are quite different, and this may have had a 454 
direct influence on their level of anti-adhesion activity. The inhibitory effect may even 455 
be due to multiple factors acting synergistically within a particular test material. Also, 456 
these dairy powders exhibited varying levels of efficacy depending on (a) whether 457 
they were used in PBS-HA or S-HA systems and (b) whether they had been subjected 458 
to enzyme treatment. The latter is further complicated by the fact that the enzyme 459 
used throughout this study was a crude PPL mixture, that contains both protease and 460 
lipase constituents (Birner-Grunberger, Scholze, Faber, & Hermetter, 2003), which 461 
could hydrolyse protein and fat components of the dairy powders, respectively.  462 
If protein levels of each test material are compared, WPI contains the highest 463 
level of protein, yet was found to be a poor inhibitor of S. mutans adhesion to HA. 464 
AWPC80 contains less protein than WPI, but exhibited high levels of anti-adhesion 465 
activity. Interestingly, SWPC80 contains almost the same level of protein as 466 
AWPC80, but was a less effective inhibitor than AWPC80. However, the lactose 467 
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content of SWPC80 was almost three times greater than that of AWPC80, and may 468 
have been detrimental to the anti-adhesion activity of this dairy powder. Results from 469 
the present study show that lactose promoted adherence of S. mutans to PBS-HA 470 
(Table 2), and this may help explain why powders with high lactose contents (WP and 471 
DW) exhibited poor anti-adhesion activity. Further to this, it could be speculated that 472 
these dairy powders did indeed possess some anti-adhesion activity but this may have 473 
been negated by their high lactose content. On the other hand, BMP and CP contained 474 
lower levels of protein than both AWPC80 and SWPC80, and also had considerable 475 
lactose levels, yet these dairy powders were potent inhibitors of S. mutans adherence 476 
to HA. It is worthwhile to note that these dairy products (BMP and CP) contain 477 
caseins, which are well known to inhibit adherence of S. mutans to HA (Vacca-Smith, 478 
Van Wuyckhuyse, Tabak, & Bowen, 1994). It may be the case that whey protein(s) is 479 
responsible for the inhibitory activity exhibited by the WPC80s, while casein fractions 480 
may be contributing to the anti-adhesion activity caused by BMP and CP. Another 481 
possible explanation for the variation in the anti-adherence activity of the various 482 
powders may be the differences in fat content, in that in general, only the powders 483 
with fat contents higher than c. 8% exhibited high levels of inhibition. Furthermore, it 484 
could be speculated that anti-adhesion activity of any dairy powder is due to the 485 
presence of both protein and fat, and it may be the case that fat is required in order for 486 
protein(s) to effectively associate with HA and consequently reduce adherence of S. 487 
mutans, as evidenced by the greater level of association of protein to HA in the case 488 
of AWPC80 than was observed for WPI.     489 
 At the outset of this study, it was anticipated that enzyme treatment would 490 
enhance the anti-adhesion efficacy of the dairy powders, as a patent by Brady & Folan 491 
(2003) claimed the adhesion inhibitory properties of a lactose-free commercial whey 492 
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product were activated upon hydrolysis. In addition, it has been reported that certain 493 
antimicrobial substances present in milk and dairy-based products (such as peptides 494 
and fatty acids) only become active following enzymatic digestion (Lopez-Exposito & 495 
Recio, 2006). However, in the present study the anti-adhesion efficacy of all dairy 496 
powders was, in general, reduced following enzyme-treatment for both PBS-HA and 497 
S-HA. For the S-HA assays, the efficacy of SWPC80, AWPC80, SWPC35 and CP 498 
was slightly (but not necessarily significantly) increased by enzyme treatment at the 499 
maximum concentration (125μg mL-1) only. Lower levels of anti-adhesion activity 500 
following enzyme treatment may have been due to hydrolysis of proteins and/ or fats, 501 
as no consistent trend was observed in order to determine whether protein or fat 502 
digestion caused the reduction in efficacy.  503 
A previous investigation by this research group which sought to determine the 504 
effect of a range of whey products on the adherence of foodborne pathogens to 505 
intestinal cells found that hydrolysis generally increased the inhibitory activity of 506 
these test materials (Halpin et al., 2009). However, the study in question employed a 507 
model system in which bacterial cells were incubated with epithelial cells, unlike the 508 
present study where bacteria were incubated with a mineral surface (hydroxylapatite) 509 
in the presence and absence of saliva. Thus, it may be that the efficacy of test 510 
materials, and hydrolysates thereof, is dependent on the surface to which 511 
microorganisms are adhering to. 512 
Another aspect of the present study was to examine the effect of various dairy 513 
powders on the growth of S. mutans. Of the range of test materials, only ET SWPC80 514 
caused a substantial and significant (P<0.05) reduction in the growth of S. mutans. 515 
SPME/GC analysis confirmed the presence of the free fatty acids butyric (C4) and 516 
caproic (C6) acids in the SWPC80 hydrolysates, and it is possible that other FAs were 517 
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present in the hydrolysed product, as milkfat contains a broad spectrum of FAs. 518 
Studies by Sprong et al. (2001, 2002) have demonstrated the antibacterial activity of 519 
milk-lipids. However, the inhibitory activity of ET SWPC80 could equally be due to 520 
peptides produced during enzymatic digestion. Peptides liberated from GMP by the 521 
action of proteolytic enzymes in PPL may also have contributed to the observed 522 
antibacterial effect. A study by Malkoski, Dashper, O’Brien-Simpson, Talbo, Macris, 523 
Cross, & Reynolds (2001) showed that kappacin, a peptide derived from κ-casein, 524 
inhibited growth of plaque-forming bacteria, and although not established here, it is 525 
possible such peptides derived from GMP are contributing to the observed 526 
antimicrobial activity of ET SWPC80. Alternatively, growth inhibition of S. mutans 527 
due to ET SWPC80 may have been the result of a synergistic effect between FAs and 528 
peptides released during enzyme treatment. Small peptides exhibiting antimicrobial 529 
properties have been proposed as alternatives to antibiotics (Mor, 2003). The oral 530 
cavity is considered eminently suitable for the application of such peptides as it 531 
provides direct access to bacterial biofilms on non-shedding surfaces (Dashper et al., 532 
2007). Currently, there is considerable commercial interest in the isolation and 533 
characterisation of dairy-derived bioactive peptides that can be added to products such 534 
as toothpastes, gels and mouth rinses (Aimutis, 2004). Our results show that an 535 
enzyme-treated whey product exhibits antibacterial effects, without isolation of 536 
individual peptides or FAs. Therefore, an antibacterial agent can be produced from 537 
whey, which is available in large quantities and is relatively inexpensive.  538 
In conclusion, the results presented here have shown that UT dairy powders 539 
are effective inhibitors of S. mutans adherence to both PBS-HA and S-HA. In general, 540 
the anti-adhesion efficacy of these dairy powders was, for the most part, reduced 541 
following enzyme-treatment. However, some activity was observed following 542 
 23 
enzymatic digestion, in particular for AWPC80, SWPC80, CP and BMP in both PBS-543 
HA and S-HA assays. It was also evident that ET SWPC80 is an effective 544 
antimicrobial agent active against S. mutans. An interesting observation of the present 545 
study is that although hydrolysis of a particular whey product may on the one hand 546 
increase the antimicrobial activity, it may do so at the expense of the potential anti-547 
adhesion activity of the product. In other words, enzyme-treatment of dairy products 548 
may enhance antimicrobial activity while suppressing their anti-adhesion efficacy. 549 
Nonetheless, this present study has shown that dairy powders, which are natural 550 
products and are readily available and relatively inexpensive materials, may offer 551 
protection against caries in both normal and dry-mouth contexts. 552 
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Legends for Figures: 664 
Figure 1: SDS-PAGE showing protein bands present in centrifuged supernatants of 665 
sweet whey protein concentrate (WPC) 80, acid WPC 80 and sweet WPC 35, both 666 
with and without prior incubation with hydroxylapatite. 667 
Lanes: 2= low range markers (range= 6,500-66,000 Da), 3= AWPC80, 4= AWPC80 668 
supernatant after incubation with HA, 5= SWPC80, 6= SWPC80 supernatant after 669 
incubation with HA, 7= SWPC35, 8= SWPC35 after incubation with HA and 9= wide 670 
range markers (range= 6,500-205,000 Da). 671 
Figure 2: Effects of Enzyme-Treated Sweet WPC80 on the growth of S. mutans, at 672 
5mg mL-1 (○), 2.5mg mL-1 (□), 1.25mg mL-1 (Δ), 0.6mg mL-1 (●) and control growth 673 
in the absence of inhibitor (■). 674 
Data= mean ± standard deviation, n=4. 675 
 676 
 677 
 678 
 679 
 680 
 681 
 682 
 683 
 684 
 685 
 686 
 687 
 688 
 29 
Figure 1: 689 
 690 
Footnotes: Bands representing bovine serum albumin (BSA), β-lactoglobulin and α-691 
lactalbumin correspond to the markers labelled at 66 kDa, 18 kDa and 14k Da, respectively. 692 
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Figure 2: 708 
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Table 1: Compositional analysis of dairy powders used in this study (g/ 100g) 725 
 SWPC80 AWPC80 SWPC35 WPI WP DW BMP CP 
Protein 75.5 78.2 34.3 86.6 12.5 13 30.2 16.4 
Fat 8 7.7 3.4 0.1 1 1.8 10.8 49.1 
Moisture 7.5 6.3 5.4 5.8 3.1 3.5 3.9 2.1 
Ash 3 5.9 6.2 2.6 9.5 0.8 6.9 4.5 
Lactose 6 1.9 50.7 4.9 73.9 80.9 48.2 27.9 
Total 100 100 100 100 100 100 100 100 
Abbreviations: SWPC80= Sweet Whey Protein Concentrate 80, AWPC80= Acid 726 
WPC80, SWPC35= Sweet Whey Protein Concentrate 35, WPI= Whey Protein Isolate, 727 
WP= Whey Powder, DW= Demineralised Whey, BMP= Buttermilk Powder and CP= 728 
Cream Powder.  729 
 730 
 731 
 732 
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 737 
 738 
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Table 2: Proportion of S. mutans (%) not adhering to PBS-HA in the presence of dairy powders at various concentrations. 739 
  (i) Untreated (ii) Enzyme-Treated 
μg mL-1 Control* 31.25 62.5 125 31.25 62.5 125 
 15.1 ±4.6 (w)       
SWPC80  21.6 ±5.8a,b (x)  39.2 ±6a (y) ¥ 66.5 ±5.9a (z) ¥ 24.6 ±0.9a (x) 29.9 ±3.3a,b (x) 37.8 ±4.2a (y) 
AWPC80  60.1 ±11c (x) ¥ 82.7 ±2.6b (y) ¥ 92.7 ±1.9b (z) ¥ 16.5 ±3a,b (w) 17 ±3.4c (w) 18.6 ±4.4b (w) 
SWPC35  17.8 ±4.9a,b (w,x) 23.3 ±6c,d (y) 50 ±9.4c (z) ¥ 20.1 ±4.4a,b (w,x) 19.7 ±4.8c,d (w,x,y) 20.5 ±4.9b (w,y) 
WPI  25.2 ±11.4a,b (x,y) 32.2 ±12.4a,c (x,y) ¥ 42.9 ±20.1c (z) ¥ 16.3 ±1.8a,b (w) 15.7 ±2.5c (w) 16.8 ±3.1b (w) 
WP  12.2 ±2.3b (w)  13.7 ±2.1d (w,x)  20.6 ±1.7d,e (x)  14.6 ±2.3b (w) 14.4 ±3.6c (w) 15 ±3.6b (w) 
DW  14.4 ±6.3b (w)  15.5 ±4.1d (w)  35.5 ±11.8c,d (x) ¥ 18.2 ±1.4a,b (w) 16.3 ±3.1c (w) 18.7 ±5.2b (w) 
BMP  28.2 ±5.3a (x)  53.2 ±7.9e (y) ¥ 83.8 ±6.4b (z) ¥ 22.5 ±4.2a,b (x) 25 ±3.2b,d (x) 27.9 ±4.2c (x) 
CP  45.9 ±13.1d (x) 70.4 ±12.2f (y) ¥ 83.5 ±9.8b (z) ¥ 38.2 ±14.7c (x) 35.8 ±7a (x) 39.2 ±6.8a (x) 
EggAlbumin†  17.4 ±5.4a,b (w) 18 ±6.3d (w) 15.7 ±6.6e (w)    
Lactose††  5.8 ±1.1 (x) 5.8 ±1 (x) 5.9 ±0.9(x)    
Footnotes:  740 
Data presented represent the means (± SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly 741 
(P<0.05) different.  Data within each row bearing different superscripts (x,y,z) show significant (P<0.05) differences between concentrations 742 
within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript ‘w’. 743 
¥ denotes significant difference (P<0.05) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.  744 
*n=60, †= egg albumin is included for the sake of comparison only as a protein control. †† lactose n=2. 745 
Abbreviations: 746 
SWPC80= Sweet Whey Protein Concentrate 80, AWPC80= Acid WPC80, SWPC35= Sweet Whey Protein Concentrate 35, WPI= Whey Protein 747 
Isolate, WP= Whey Powder, DW= Demineralised Whey, BMP= Buttermilk Powder and CP= Cream Powder.  748 
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Table 3: Proportion of S. mutans (%) not adhering to S-HA in the presence of dairy powders at various concentrations. 750 
  (i) Untreated (ii) Enzyme-Treated 
μg mL-1 Control* 31.25 62.5 125 31.25 62.5 125 
 36.8±7.7 (w)       
SWPC80  72.7 ±6.2a,b,c (x) ¥ 82.8 ±7.3a (x) ¥ 76.4 ±7.8a (x) 52.8 ±8.8a,b (x) 60.9 ±14.9a (x) 80.3 ±0.5a (y) 
AWPC80  74.7 ±1.7a,b (x) ¥ 76.3 ±3.5a,b (x) ¥ 75.2 ±7.1a (x) 50.9 ±7.6a,b (x) 57.7 ±11.1a (x) 86.4 ±13.7a (y) 
SWPC35  53.1± 16.7d (x) 58.7 ±12c,d (x) 55 ±7.6b (x) ¥ 47.9 ±11.3a,b (x) 52.2 ±10.1a (x) 78.3 ±8.6a (y) 
WPI  50.9 ±7.5d (x) 54.6 ±1.5c,d (x) ¥ 55.2 ±7.9b (x) ¥ 37.6 ±7.1b (w) 39.3 ±5.9a,b (w) 42.4 ±2.1c (w) 
WP  61.6 ±2.7b,c,d (x) ¥ 79.3 ±1.8a (y) ¥ 73.5 ±9.3a (x,y) ¥ 33.9 ± 3.6b (w) 40.3 ± 5.8a,b (w) 42.7 ±4.9c (w) 
DW  61.4 ±4.7b,c,d  (x) ¥ 65.1 ±3.1b,c (x) ¥ 62.6 ±5.1a,b (x) ¥ 34.8 ±5b (w) 33.7 ± 10.8b (w) 42.8 ±6.4c (w) 
BMP  71.8 ± 1.6a (x) ¥ 63.2 ± 1.8b,c,d (y,z) ¥ 59.2 ± 1.8b (y,z) ¥ 44.6 ±2.7a,b (x) 40.8 ±5a,b (w,x) 42 ± 4.9c (w,x) 
CP  58 ±10c,d (x) 63.1 ±15b,c,d (x) 59.2 ±7.3b (x) ¥ 56.3 ±7.8a (x) 52.6 ±10.7a (x) 74 ±9.9a (y) 
EggAlbumin†  47.6 ±9.2d (x) 48.9 ±7d (x) 57.3 ±13.8b (x)    
Footnotes:  751 
Data presented represent the means (± SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly 752 
(P<0.05) different.  Data within each row bearing different superscripts (w,x,y,z) show significant (P<0.05) differences between concentrations 753 
within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript ‘w’. 754 
¥ denotes significant difference (P<0.05) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.  755 
*n=60, †= egg albumin is included for the sake of comparison only as a protein control. 756 
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Table 4: Initial concentrations of various test materials and quantity of protein in the test material interacting with hydroxylapatite (n=1).  758 
 759 
μg protein per mg HA 
Quantity of Test 
Material (μg mL-1) 
SWPC80 AWPC80 SWPC35 WPI BMP CP 
31.25 3 4.9 2.2 4 1 0 
62.5 5 9.1 4.2 9 4 3 
125 10.5 19 7.8 15 8 7 
250 14.0 28.5 8.2 23 15 13 
500 21.4 60.3 8 27 26 N/ D 
Abbreviations: 760 
SWPC80= Sweet Whey Protein Concentrate 80, AWPC80= Acid WPC80, SWPC35= Sweet Whey Protein Concentrate 35, WPI= Whey Protein 761 
Isolate¸BMP= Buttermilk Powder and CP= Cream Powder  762 
